Abstract
Fifteen patients with locally advanced or metastatic bladder carcinoma and with cardiac and/or renal impairment were treated with a combination of 5-fluorouracil, 400 mg/m2, epirubicin, 40 mg/m2, and cyclophosphamide, 400 mg/m2. No complete or partial remissions were observed among the 14 evaluable patients. The toxicity level was very low. We are now trying to "tailor" platinum-based combinations to renal function.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Transitional Cell / drug therapy*
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / therapeutic use
-
Drug Administration Schedule
-
Epirubicin / administration & dosage
-
Epirubicin / therapeutic use
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
Pilot Projects
-
Risk Factors
-
Urinary Bladder Neoplasms / drug therapy*
Substances
-
Epirubicin
-
Cyclophosphamide
-
Fluorouracil